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The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by
peptide/majorhistocompatibilitycomplexIIandanadditionalsignaldeliveredbycostimulatorymolecules.Thebestcharacterized
costimulatorymoleculesbelongtoB7/CD28andTNF/TNFRfamiliesandplaycrucialrolesinthemodulationofimmuneresponse
and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment,
where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting
costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers.
Here, latest therapeutic approaches targeting costimulatory molecules will be described.
1.Introduction
T-cell activation requires a double signal, as stated in the
“two signal theory.” The ﬁrst signal is provided by the
engagement of the T-cell receptor (TCR) by its cognate anti-
gen, through the interaction with the peptide-major-histo-
compatibility complex (MHC) on antigen presenting cells
(APCs). In 1987, Jenkins et al. [1] demonstrated that TCR
engagement was not suﬃc i e n tf o raf u l lT - c e l la c t i v a t i o n .
Costimulatory molecules expressed on the surface of APCs
areresponsibleforthesecondsignal,knownascostimulatory
signal.Theinteractionsofcostimulatorymoleculeswithcog-
nate receptors on the surface of T cells result in clonal T-cell
expansion and diﬀerentiation, as well as in carrying out their
eﬀector functions [2]. For several costimulatory molecules
a bidirectional signaling has been reported, because their
signaling pathways are also directed toward APCs. The lack
of costimulation results in a nonresponsive state of T cells,
known as anergy [3]. Following the initial activation, coin-
hibitory molecules are induced to dampen the immune
response. Complex interactions implicating both overlap-
ping and distinct costimulatory pathways underlie the gen-
eration of the immune response; thus, the tightly regulated
expression of costimulatory and coinhibitory molecules,
both in time and space, is crucial to provide an eﬃcient im-
mune protection avoiding autoimmunity.
Costimulatory molecules belong to two major families:
B7/CD28 family and tumor necrosis factor (TNF)/tumor
necrosis factor receptor (TNFR) family. All molecules be-
longing to B7/CD28 family are members of the larger im-
munoglobulin superfamily and are involved in the triggering
of cell-mediate immune response. Instead, the TNF/TNFR
family members are involved in the later phases of T-cell
activation and are induced from hours to days following the
TCR engagement [2].
The presence of an eﬃcient costimulation is crucial for
improving antitumor immunity. In fact, one of the mecha-
nisms through which tumors are able to evade immune
surveillance is the lower expression of costimulatory mole-
cules or the upregulation of coinhibitory molecules. The lack
of costimulation in the tumor microenvironment could be
responsible for the generation of anergic T cells and, con-
sequently, the absence of an appropriate antitumor immune
response [4].
This paper focuses on the major costimulatory pathways
belonging to B7/CD28 and TNF/TNFR families, underlying2 Journal of Biomedicine and Biotechnology
the potential of targeting these pathways in cancer immuno-
therapy.
2. The B7:CD28 Family
2.1. B7-1/B7-2:CD28/CTLA-4. The B7-1/B7-2:CD28/CTLA-
4 pathway is the best characterized pathway of T-cell
costimulation and coinhibition and symbolizes the classical
way where the ligand can bind two receptors for regulating
both T-cell activation and tolerance. The balance between
the activating and inhibitory signals derived from the
engagement of CD28 and CTLA-4, respectively, is crucial to
assure protective immunity, without falling into undesired
autoimmunity.
B7-1 (CD80) and B7-2 (CD86) are two ligands for both
CD28 and CTLA-4. The expression of B7-1 and B7-2 is
restrictedtoprofessionalAPCs,suchasdendriticcells(DCs),
macrophages, and B cells. CD28 is constitutively expressed
on the surface of T cells, whereas CTLA-4 expression is
induced 24–48 hours after T-cellactivation, due to the action
of lymphocyte cell kinase (Lck), Fyn and resting lymphocyte
kinase (RLK) that phosphorylates CTLA-4, thus increasing
its transport to the cell surface and preventing its internal-
ization. CTLA-4 was shown to have higher aﬃnity for both
B7-1 and B7-2 than CD28 receptor [4, 5].
The B7-1/B7-2:CD28 pathway is the strongest costimu-
latory signal delivered by APCs to provide a full activation
of T cells, promoting their proliferation and IL-2 secretion
[4]. The intracellular signaling of B7-1/B7-2:CD28 pathway
occurs through the activation of phosphatidyl-inositol-3-
kinase (PI3K)/Akt/Nuclear Factor-κappa B (NF-κB) and the
mitogen-activated protein kinases (MAPKs) pathway, which
support cell survival, memory development, proliferation,
and cytokines production [6].
In contrast to the costimulatory signal derived from
the binding of CD28 to B7-1 and B7-2, the engagement
of CTLA-4 by these ligands provides a negative regulation
of the immune response, as proved by the characterization
of CTLA-4 deﬁcient mice (CTLA-4−/−). In fact, CTLA-
4−/− mice showed lymphoproliferative disorders that led
to neonatal death after 3-4 weeks of age, underscoring
the central role of this receptor in induction of peripheral
tolerance through a direct inhibition of CD28 signaling or
by regulating the availability of cofactors necessary for TCR
signaling [5]. Because of the lack of intrinsic enzymatic
activity, CTLA-4 binds signaling molecules, such as protein
phosphatase 2A (PPA-2) and Src homology phosphatase 2
(SHP-2), which mediate its eﬀects [5]. CTLA-4 should be
also involved in the regulation of CD4+CD25+ T regulatory
cells (Tregs), which constitutively expressed this receptor
on their surface [5]. Although still debated, part of the
inhibitory function of CTLA-4 may result from its ability
to enhance the generation of Tregs or, as an alternative, to
modulate their functions. This hypothesis is supported by
the evidence that mice with a Tregs-conditional deletion
developed lymphoproliferative syndrome [7]. In addition,
CTLA-4 blockade caused the abrogation of Treg functions in
vivo [8].
The tumor microenvironment is often characterized by
the presence of anergic T cells, due to the lack of positive
costimulatory molecules, mainly B7-1 and B7-2, on the
surfaceofcancercells[9].Onestrategytorevertthisscenario
is to force B7 expression on tumor cells, rendering them able
to activate T-cell immune response.
Several studies showed that the induction of B7-1 on
tumor cells was suﬃcient to stimulate the CD8+ Tc e l l -
mediated rejection in several tumor models, as well as a
memory response, but was insuﬃcient to mediate rejection
of poorly immunogenic tumors [4]. Several phase I clinical
trials evaluated the eﬃcacy of B7-1 transfected tumor cell
vaccines,withorwithoutIL-2,withencouragingpreliminary
results in patients aﬀected by metastatic renal carcinoma
and nonsmall cell lung cancer (Table 1)[ 10, 11]. In a phase
II trial, 39 patients with metastatic renal carcinoma were
vaccinated with B7-1-transfected autologous tumor cells in
combination with systemic IL-2 [12]. The authors observed
3% pathologic complete response, 5% partial response,
64% stable disease, 28% disease progression, and a median
survival of 21.8 months; similar results have been reported
f o rI L - 2a l o n e[ 12].
B7-1 was also included in vaccine along with speciﬁc
antigens, such as carcinoembryonic antigen (CEA) (Table 1).
Recently, in a phase II trial for metastatic colorectal cancer,
Kaufman et al. used a nonreplicating canaripox virus vector
(ALVAC) expressing CEA and B7-1 in combination with
chemotherapy. The observed objective response rate of
40.4% was similar to that reported for chemotherapy alone
[13]. Improvements on new vaccine strategies led to the
generationofviralvectorsexpressingatriadofcostimulatory
molecules (TRICOMs), such as B7-1, intercellular adhesion
molecule 1 (ICAM-1), and lymphocyte function-associated
antigen 3 (LFA-3), along with CEA, mucin-cell-surface-
associated 1 (MUC-1), and prostate-speciﬁc antigen (PSA)
antigens, with promising results in preclinical studies and
clinical trials, both in terms of eﬃcacy and safety (Table 1)
[14–18].Inthisregard,aphaseIIrandomizedcontrolledtrial
of poxiviral-based PSA-targeted immunotherapy in patients
with metastatic castration-resistant prostate cancer showed
that the treatment was well tolerated and associated with
44% reduction in the death rate [19]. Recently, multi-target
vaccineapproachesweretestedinvitro,resultinginenhanced
antitumor immune response against hepatocellular carci-
noma and glioma cell lines [20, 21].
Althoughseveralpreclinicalevidencesprovedtheeﬃcacy
of B7-1-based therapeutic strategy in the induction of
tumor antigen-speciﬁc T-cell response, meaningful clinical
improvement has been limited. In addition to the existence
of multiple mechanisms of immune resistance, a possible
explanationforthelackofmarkedclinicalbeneﬁtsisthatB7-
1andB7-2alsobindCTLA-4withhigheraﬃnitythanCD28;
therefore, it is possible that the engagement of CTLA-4 by
B7-1—expressing vaccine could limit its ability to activate
T-cell immunity. This observation opens the door for a
new therapeutic strategy: the speciﬁc blockade of CTLA-4
coinhibitory signal.
Several studies demonstrated that the blockade of CTLA-
4 using anti-CTLA-4 antibodies was capable of inducing theJournal of Biomedicine and Biotechnology 3
Table 1: Clinical trials of B7:CD28 costimulatory molecules.
Costimulatory
molecule Tumor model Therapeutic strategy Refs
B7-1
Metastatic renal carcinoma Vaccination with B7-1-transfected autologous tumor cells in
combination with systemic IL-2 [10–12]
Nonsmall cell lung cancer Vaccination with an adenocarcinoma cell line expressing
B7-1 and human leukocyte antigen A1(HLA-A1) or A2 [11]
Metastatic colorectal cancer Vaccination with ALVAC vector expressing CEA and B7-1 in




Vaccination with TRICOM vector [14–17]
CTLA-4
Metastatic melanoma, metastatic
renal cancer, nonsmall cell lung
cancer
MDX-010 Ab blockade of CTLA-4 alone or in combination
with vaccine, IL-2, and chemotherapy [32–44]
Melanoma, metastatic colorectal
cancer, advanced gastric cancer,
and esophageal adenocarcinoma
CP-675, 206 Ab blockade of CTLA-4 alone or in combination
with chemotherapy [45–53]
PD-1
Hematological malignancies CT-011 Ab blockade of PD-1 [95]
Advanced solid cancer MDX-1106 Ab blockade of PD-1 [97]
Solid Tumors MK 3475 [99]
Cancers, multiple indications MDX 1105-01 [99]
rejection of diﬀerent types of established tumors in mice,
such as colon carcinoma, ﬁbrosarcoma, prostatic carcinoma,
lymphoma, and renal carcinoma, along with a memory
response [4]. Although eﬀective as monotherapy in the
treatmentofsmallandimmunogenic tumors,a combination
of CTL-4 blockade with other immunotherapeutic strategies
is needed to treat large and poorly immunogenic tumors.
Combination of CTLA-4 blockade and irradiated tumor
vaccine expressing GM-CSF results in tumor rejection and
reduction of tumor growth in the B16 melanoma model.
Similar results were reported for the poorly immunogenic
SM1 mammary carcinoma line and a transgenic model of
prostate carcinoma [4, 22]. Moreover, the combination of
anti-CTLA-4 with DNA vaccine increased T-cell immune
response against melanoma-associated antigens and induced
B16 tumor rejection [23]. In the same tumor model, the
CTLA-4 blockade combined with CD25+ Treg depletion
and vaccination was reported to be eﬀective in inducing
tyrosinase-related-protein-2-(TRP-2-) speciﬁc CD8+ Tc e l l s
and in rejecting larger tumor loads [24]. An increased
antitumor immunity in B16 melanoma model was reported
following CTLA-4 blockade with peptide vaccine and a
synthetic oligodeoxynucleotide (ODN)asadjuvant[25].The
use of anti-CTLA-4 along with radiotherapy led to the im-
provement of survival rate in a mouse model of metastatic
breast cancer, whereas CTLA-4 blockade in combination
with chemotherapy provided clinical beneﬁts in the murine
myeloma model MOPC-315 [26, 27].
The encouraging results obtained in preclinical models
led to the development of two fully humanized anti-CTLA-
4 antibodies, MDX-010 (ipilimumab), and CP-675,206
(tremelimumab) (Table 1). Ipilimumab is an IgG1 with a
plasma half-life of 12–14 days, and it has been approved by
the FDA in March 2011 for the treatment of advanced
melanoma (Bristol-Myers Squibb, Princeton, NJ, USA).
Tremelimumab is an IgG2 with a plasma half-life of approx-
imately 22 days (Pﬁzer, New York, NY, USA). Both agents
are able to recognize human CTLA-4 and block the inter-
action of CTLA-4 with CD80 or CD86, but their exact
mechanism of action is not fully understood. Recently, some
authors reported that tremelimumab induces a signiﬁcant
increase in CD8+ cells intratumoral inﬁltration and that the
immune response mediated by this agent is due to a direct
activation of eﬀector T cells rather than a depletion of Tregs
[28, 29]. Preliminary data about an increase in antigen-
speciﬁc eﬀector T cells following ipilimumab treatment in
combination with vaccine in three melanoma patients are
also published [30].
I p i l i m u m a ba n dt r e m e l i m u m a bw e r et e s t e di no v a r i a n ,
breast, prostate, colon carcinoma, and, mainly, in melanoma
and renal cell cancer clinical trials [31]. Several early phase
II studies evaluated ipilimumab in metastatic melanoma,
reportinganobjectiveresponseraterangingfrom6%to21%
and a disease-control rate of about 30% [32–34]. Recently, a
multicenter single arm phase II study evaluated the eﬃcacy
and the safety of ipilimumab monotherapy in patients
with pretreated advanced melanoma. Patients (n = 155)
were treated with ipilimumab at 10mg/kg and the authors
showed that one- and 2-year survival rates were 47.2%
and 32.8%, respectively, with a median overall survival
of 10.2 months [35]. Moreover, a randomized, double-
blind, placebo-controlled, phase II trial of ipilimumab at
10mg/kg, with or without budesonide, in 115 patients with
unresectable stage III or IV melanoma, showed that 2-year
survival rate was approximately 40% in each arm [36]. In
another randomized, double-blind, multicenter, phase II,
dose-ranging study, 217 melanoma patients were randomly
assigned to receive ipilimumab at 10mg/kg (n = 73),4 Journal of Biomedicine and Biotechnology
3mg/kg (n = 72) or 0.3mg/kg (n = 72). The authors
observed a dose-dependent antitumor eﬀect of ipilimumab,
with the best overall response of 11.1% in patients treated
with 10mg/kg [37]. Ipilimumab was also tested in combina-
tion with other therapeutic agents such as IL-2, vaccine or
chemotherapy, such as dacarbazine [38–42]. In particular,
interesting results came from the phase III trial by Hodi
et al.; in this study, melanoma patients were randomized
to receive ipilimumab 3mg/kg, with or without a gp100
peptide vaccine, or the vaccine alone. The primary endpoint
of the study was the overall survival. The median overall
survival was approximately 10.0 months among patients
receiving ipilimumab (with or without gp100 vaccine), as
compared with 6.4 months among patients receiving gp100
alone [41]. In another phase III study, the administration
of ipilimumab (at a dose of 10mg/kg) in combination with
dacarbazine was associated with a signiﬁcant improvement
in overall survival among patients with previously untreated
metastatic melanoma [42]. Ipilimumab was also tested in
othertypesofmalignancies.InaphaseIIstudyon61patients
aﬀected by metastatic renal cell carcinoma, ipilimumab was
administrated at a dose of 1mg/kg or 3mg/kg; ﬁve of 40
patients treated with 3mg/kg had a partial response [43]. A
recent phase II study compared the addition of ipilimumab
to carboplatin and paclitaxel chemotherapy in nonsmall
cell lung cancer patients. Ipilimumab was administered
either concurrently or in a phased schedule after receiv-
ing the ﬁrst two cycles of chemotherapy. Patients treated
with ipilimumab plus chemotherapy, in concurrent and
sequential regimens, showed an improved overall survival
compared with patients receiving chemotherapy alone [44].
Tremelimumab was ﬁrst evaluated in the treatment of
metastatic melanoma. A phase I clinical trials evaluating
the maximum-tolerated dose of tremelimumab showed
antitumor activity of this drug in melanoma patients [45].
Other phase I/II studies reported SD occurring in about
30% of melanoma patients treated with tremelimumab and
an objective antitumor response in 10% of patients [46–
48]. A phase II study evaluated the antitumor activity
of 15mg/kg tremelimumab in 246 patients aﬀected by
melanoma, reporting an objective response rate of 6.6%,
with duration of response ranged from 8.9 to 29.8 months
[49]. A phase III trial of tremelimumab in combination with
DTIC or temozolomide was recently withdrawn, because
of the lack of a survival advantage in the tremelimumab
group [50]. Tremelimumab was also tested in cancers others
than melanoma, both as monotherapy and in combination
therapy, such as metastatic renal cell carcinoma, metastatic
colorectal cancer, and advanced gastric and esophageal
adenocarcinoma, but not signiﬁcant clinical improvements
were reported [51–53]. The treatment with both ipilimumab
and tremelimumab is associated with inﬂammatory adverse
events like rash, diarrhea, colitis, and hypophysitis; this side
eﬀect proﬁle could be linked to the potentiation of Th17 cell
diﬀerentiation following CTLA-4 blockade [54].
2.2. ICOS-L:ICOS. The inducible costimulator (ICOS,
CD278) is a costimulatory receptor that is weakly expressed
on na¨ ıve T cells and quickly upregulated in activated CD4+
and CD8+ T cells. A constitutive expression of ICOS by
CD25+CD4+Foxp3+ Tregs has also been reported [55]. The
cognate ligand for ICOS is ICOS-L (B7h, B7RP-1, CD275),
which is expressed by professional APCs and by peripheral
epithelial and endothelial cells following TNF-α stimulation
[56].TheICOS:ICOS-Lpathwayprovideakeycostimulatory
signal for T-cell proliferation and, mainly, for T-cell survival
[57]. Moreover, ICOS regulates development and response
of T follicular helper (Tfh), Th1, Th2, Th17 cells and plays
rolesinthemaintenanceofmemoryeﬀectorTcellsandTregs
homeostasis [57]. The observation that immune defects in
CD28 knockout mice can be reverted by crossing them with
sanroque mice, which express ICOS constitutively, suggested
that the two receptors activated similar intracellular path-
ways [58]. In fact, ICOS is able to trigger the PI3K/Akt
pathway greater than CD28 and to activate the downstream
MAPKs cascade [59]. Due to its role in sustaining T-cell
activation and eﬀector functions, targeting ICOS:ICOS-L
could represent a plausible approach to enhance antitumor
immunity.TheICOS-Lcostimulation,throughitsexpression
on tumor cells, was capable of inducing cancer regression in
Sa1/NﬁbrosarcomaandJ558plasmacytomamodels[60,61].
Systemic treatment with murine ICOSL-IgG fusion protein
was eﬀective in promoting INF-γ-dependent antitumor im-
munity in MethA ﬁbrosarcoma and B16F1 melanoma tumor
models[62].RecentdatashowedanincreaseofICOShi CD4+
eﬀector T cells percentage after CTLA-4 blockade in several
cancer models. In addition, upon CTLA-4 blockade, this cell
population produced greater levels of INF-γ than ICOSlo
CD4+ Tcells,suggestingthatICOScouldbeusedasamarker
for CD4+ eﬀector T-cell response [63–66]. A downregulation
ofICOSwasshownincoloncancerpatientsand theexpression
of ICOS in tumors was associated with a greater survival
of melanoma patients [67, 68]. A recent study investigated
the role of ICOS in the Tregs in melanoma, demonstrating
the selective expression of ICOS on a “hyperactivated” Treg
population that strongly inhibits T-cell response through IL-
10-mediated APCs suppression [69]. Moreover, ICOS-L was
expressed by both cultured and freshly isolated melanoma
cells from stage IV melanoma patients and could provide
costimulation through ICOS for the activation and expan-
sion of Tregs in the tumor microenvironment, as another
mechanism of escape from immune surveillance [70]. Thus,
targeting costimulatory and coinhibitory molecules on Tregs
might be a promising approach for modulating peripheral
tolerance in cancer patients.
2.3. PD-L1/PD-L2:PD-1. Programmed cell death 1 (PD-1) is
a negative costimulatory receptor belonging to the B7/CD28
family. PD-1 expression is induced on activated T cells, B
cells, monocytes, DCs, and, at low levels, on natural killer
T cells (NKT) [71]. Negative costimulatory signals mediated
via PD-1 and CTLA-4 are not redundant; in fact PD-1
mainly acts in regulating inﬂammatory responses in periph-
eral tissues, whereas CTLA-4 modulates T-cell priming in
lymphoid organs. In addition, in contrast to CTLA-4, PD-1
isabletoblockTCR-andCD28-mediatedactivationthrough
the recruitment of inhibitory phosphatases, such as SHP-2,
which inhibits the induction of PI3K activity [71].Journal of Biomedicine and Biotechnology 5
PD-1 has two known ligands belonging to the B7 family:
PD-L1 (B7-H1) and PD-L2 (B7-DC). To date, one of
the major diﬀerences between these ligands concerns their
expression pattern. PD-L1 mRNA is broadly expressed in
multiple peripheral tissues such as heart, placenta, muscle,
fetal liver, spleen, lymph nodes, and thymus; PD-L1 protein
has been found in activated T cells, B cells, monocytes, DCs,
in endothelial cells and myocardium and can be upregulated
followingexposuretotypeIortypeIIinterferon,providinga
negative feedback mechanism to dampen immune response
[71]. On the contrary, PD-L2 expression is largely restricted
to activated macrophages and DCs, but only PD-L2 mRNA
can also be observed in the human heart, placenta, lung,
and liver [72]. The function of PD-L1 and PD-L2 has been
debated, owing to conﬂicting results about the costimulatory
signal provided by the ligands. Opposite results have been
obtained using PD-L1 fusion protein and mAbs, but, to
date, the accepted opinion is that PD-1/PD-L1 interaction
generally produces a negative costimulatory signal [69]. The
same controversial results has been reported about PD-
L2, with one group demonstrating a negative costimulatory
role for this ligand, and another group reporting that PD-
L2 was able to stimulate T cells [72]. In vivo data from
PD-L2 deﬁcient mice supported a stimulatory function of
PD-L2. Anyway, the disagreeing results concerning PD-L1
and PD-L2 roles may be explained by the existence of
another receptor able to bind these ligands that have positive
costimulatory functions, like CD28 [73].
PD-L1 aberrant expression has been reported in many
human cancers, such as glioblastoma, melanoma, and can-
cers of the head and neck, lung, ovary, colon, stomach, kid-
ney, and breast [74, 75]. Moreover, in several follow-up stud-
ies, the expression of PD-L1 correlates with a poor prognosis
of patients [76–82]. Based on these experimental evidences,
PD-L1 blockade has been proposed for cancer immuno-
therapy. Two independent studies have shown that forced
expression of PD-L1 in the murine myeloma cell line P815
render them more resistant to in vitro cytolysis and less
susceptibletorejectionthancontrolwheninoculatedinmice
[83, 84]. In addition, the treatment with anti-PD-L1 mAbs
was capable of inhibiting the growth of P815-PD-L1 in
vivo [84]. PD-1 blockade was able to restore the antitumor
immunity to accelerate tumor eradication in murine squa-
mous cancer cell line SCCVII, in P815 cell line and to block
both CT26 colon carcinoma metastasis to the lung and B16
melanoma metastasis to the liver [85–87]. In vivo studies
in these tumor models examined the combination of anti-
PD-1 mAb with GM-CSF-secreting tumor cell vaccine and
reportedthattheadministrationofantiPD-1mAbenhanced
the eﬃcacy of vaccine increasing number and activity of
tumor-speciﬁc CD8+ T cells [88]. A recent study reported
that the combination of PD-1 blockade and NKT cell activa-
tion results in increased antitumor responses in a melanoma
model [89]. A reduced number of Tregs at the tumor
site was observed after the treatment with anti-PD-1 mAb
and the Toll-like receptor agonist CpG, suggesting that it
could be another mechanism by which PD-1 blockade exerts
antitumor eﬀects [90]. The expression of PD-L1 on DCs is
also able to block antitumor T-cell response; myeloid DCs
expressing PD-L1 isolated from ovarian cancer poorly stim-
ulated T cells and PD-L1 blockade could revert this scenario
[91]. In addition, the anti-PD-L1 therapy was observed to
revitalize “exhausted” antiviral CD8+ T cells in animals with
chronic viral infections [92]. The promising results in pre-
clinical models have led to the development of two human-
ized antibodies against PD-1 receptor that block its interac-
tion with PD-L1:CT-011 and MDX-1106 (Table 1). A pre-
clinical study evaluated the combination of CT-011 with
low dose of cyclophosphamide and with a tumor vaccine;
the authors reported the complete regression of established
tumors in most of the animals treated [93]. Benson et al. re-
ported that CT-011 enhances NK-cell migration toward
malignant plasma cells in multiple myeloma [94]. To date,
only phase I clinical trials have been conducted to evaluate
both eﬃcacy and safety of these two agents. In a phase I trial
enrolling 17 patients with advanced hematological malig-
nancies, the treatment with CT-011 at doses ranging from
0.2 to 6mg/kg led to clinical improvement in 33% of patients
[95]. Recently, the administration of CT-011 in combination
with autologous dendritic cell/myeloma fusion-vaccine was
demonstrated to stimulate T-cell responses after vaccine
administration [96]. The eﬃcacy of MX-1106 was evaluated
in a phase I study enrolling 39 patients with advanced
solidcancers(melanoma,colorectalcancer,castrate-resistant
prostate cancer, nonsmall-cell lung cancer, and renal cell
carcinoma) obtaining very promising results; phase II and
III trials are under evaluation [97]. In particular, it will
be interesting to evaluate the combination of anti-PD1
with other agents, such as anti-CTLA-4 mAb, vaccines, and
chemotherapy. Several phase II clinical trials are testing the
safetyandtheeﬃcacyofthesetwoPD-1antibodiesinseveral
types of cancer [98]. MK-3475 and MDX-1105-01 are other
two antibodies against PD-1 and PD-L1, respectively, which
are currently being investigated in phase I clinical trials
(Table 1)[ 99].
2.4. HVEM:BTLA/CD160. The B- and T-lymphocyte atten-
uator (BTLA) is another member of the B7/CD28 family
acting as a negative costimulatory receptor [100]. The
constitutive expression of BTLA has been reported, at low
levels, on na¨ ıve B and T cells, Tfh, macrophages, DCs,
NKT cells, and natural killer cells (NK), but unlike CTLA-
4 and PD-1, BTLA is not expressed on Tregs [100]. BTLA
expression is upregulated following T-cell activation [101].
Moreover, like PD-1, BTLA seems to have a role in inducing
CD8+ T-cell exhaustion during chronic viral response.
The herpes virus entry mediator (HVEM), a member of
TNFR superfamily, has been identiﬁed as BTLA ligand.
HVEM expression is high in na¨ ıve T and B cells, but it
decreases during T-cell activation. HVEM is also expressed
on DCs, Tregs, monocytes, NK cells, and neutrophils, and in
nonhematopoietic cells, such as parenchymal cells [100].
In addition to BTLA, HVEM binds also CD160, an-
other member of the B7/CD28 family. CD160 is highly
expressed on CD56dimCD16 NK cells, NKT cells, γδ T cells,
CD8+CD28− T cells, a small subset of CD4+ cells and
intestinal intraepithelial T cells (IEL) [100].6 Journal of Biomedicine and Biotechnology
HVEM also interacts with LIGHT (described below in
the text) and lymphotoxin alpha (LTα)o fT N F Rf a m i l y ,
being the unique example of a direct interaction between
the two families [102]. Therefore, HVEM is considered
a molecular switch, because of its ability to regulate the
immune response depending on which cognate ligand binds.
In contrast to LIGHT and LTα engagement, which generally
delivers positive costimulatory signals, HVEM engagement
of BTLA and CD160 provides negative costimulatory signals
to T cells [100, 102] .T h er o l eo fB T L Aa san e g a t i v e
costimulatory receptor has been shown by the phenotype of
BTLAdeﬁcientmice,whichweremoresusceptibletodevelop
autoimmune disorders, and by the in vitro observation
that anti-BTLA agonists drive negative signals to T cells
[102]. The engagement of BTLA results in the inhibition
of CD3/CD28 T-cell activation. BTLA signals through the
recruitment of SHP-2 phosphatase, but the downstream tar-
get of SHP-2 is unclear. Anyway, recent studies showed that
triggering BTLA signaling in B cells resulted in blocking B-
cell proliferation through the inhibition of phosphorylation
of some transcription factors like NF-κB[ 103].
The similarity between BTLA and PD-1 signaling could
justifyapossibleuseofBTLAblockadetoenhanceantitumor
immunity. The expression of BTLA was found in chronic
lymphocytic leukemia/small lymphocytic lymphoma [104].
Moreover,solubleBTLAseemstoenhanceantitumoreﬃcacy
of the HSP70 vaccine in murine TC-1 cervical cancer mice
[105]. Recently, a study by Derr´ e et al. demonstrated the
potentiality of targeting BTLA for cancer immunotherapy,
reporting that BTLA is expressed on tumor antigen-speciﬁc
CD8+ T cells from melanoma patients and that this molecule
inhibits their fully functionality; following the vaccination
with CpG adjuvants, the authors observed a downregulation
ofBTLA,withapartialrecoveryofCD8+ Tcellsfunctionality
[106]. BTLA-HVEM blockade showed antitumor eﬀects in
murine TC-1 cervical cancer model in vivo, resulting in
downregulation of IL-10 and TGF-beta and in activation
of dendritic cells in IL-12- and B7-1-dependent manner.
Anyway, BTLA-HVEM blockade alone was not eﬀective in
eradicating the tumor, whereas the combination with HSP70
vaccine improved antitumor immunity by increasing IL-2
and INF-γ production and decreasing IL-10, TGF-beta, and
Foxp3 transcription levels in the tumor microenvironment
[107]. The evidences supporting a negative costimulatory
function for CD160 come from in vitro studies, because
CD160 deﬁcient mice have not been generated. CD160
agonists strongly inhibited CD4+ T-cell proliferation and
cytokines production and reduced INF-γ secretion by NK
cellline[108].Recently,Caietal.reportedastronginhibition
of CD3/CD28-induced T-cell activation after the use of
CD160 agonists, but the downstream intracellular pathways
involved are not known [109]. Indeed, Liu et al. reported
that CD160 is expressed in B-cell chronic lymphocytic
leukemia, in which its engagement mediates survival and
growth signals. In fact, CD160 activation was associated
with upregulation of antiapoptotic genes Bcl-2, Bcl-xL
and Mcl-1 and, consequently, with reduced mitochondrial
membrane potential collapse and cytochrome c release.
CD160 engagement also induced cell cycle progression and
proliferation [110]. A recent study examined the expression
ofCD160in811casesofB-celllymphoproliferativedisorders
(B-LPD). The authors showed that CD160 was expressed in
98% of chronic lymphocytic leukemia (CLL) cases, 100%
of hairy cell leukemia (HCL) cases, 15% of mantle cell
lymphoma (MCL) in the leukemic phase, and 16% of other
B-LPD cases, whereas it was absent in the normal B-cell
lineage [111]. Recently, Chabot et al. suggested a role for
CD160 in tumor neoangiogenesis. CD160 was expressed
on newly formed blood vessels in human colon carcinoma
and mouse B16 melanoma, but not in the healthy vessels.
Treatmentwithanti-CD160monoclonalantibodyCL1-R2in
combinationwithcyclophosphamidechemotherapyresulted
in the regression of tumor vessels in B16 melanoma-bearing
mice[112].Furtherstudiesareneededtoclarifythispathway
so as to design potential CD160/BTLA-based antitumor
therapeutic strategies.
2.5. B7-H3 and B7-H4. B7-H3 and B7-H4 (B7x, B7S1)
are two of the newer members of the B7-family. B7-H3
expression has been found to be inducible on T cells, NK
cells and APCs [113]. B7-H3 is also broadly expressed on
osteoblasts, ﬁbroblasts, and epithelial cells, as well as in liver,
lung, bladder, testis, prostate, breast, placenta, and lymphoid
organs [113]. To date, only one potential receptor of B7-H3
on activated T cells named TLT-2 has been identiﬁed [113].
There are conﬂicting data about the functions mediated by
B7-H3, as both stimulatory and inhibitory properties have
been reported. Initial studies described B7-H3 as a positive
costimulatory molecule which enhanced the proliferation of
both CD4+ and CD8+ T cells, the induction of cytotoxic
T lymphocytes (CTLs) and the production of INF-γ.B y
contrast, other studies suggested an opposite role for B7-
H3, showing that it is able to inhibit T-cell activation and
cytokines production, like IL-2 [114]. Moreover, B7-H3
blockade with antagonistic mAbs enhanced T-cell prolifer-
ation in vitro and worsened the experimental autoimmune
encephalomyelitis (EAE) in vivo, an autoimmune disorder
observedalsoinB7-H3deﬁcientmice[114].Becauseofthese
controversial results, the possible existence of additional
receptors for B7-H3 has been taken into consideration.
Recently,severalworksreportedB7-H3expressionindif-
ferent human cancers, as reviewed by Loos et al. The double
stimulatory and inhibitory nature of B7-H3 signaling also
appeared in murine cancer models and in human cancers.
TheauthorsshowedthatB7-H3expressionisassociatedboth
to favorable and adverse clinicopathologic features [113].
Due to its immunomodulatory ability, B7-H3 blockade
could be a potential anticancer immunotherapy, but the
controversial ﬁndings about its role remain to be elucidated.
B7-H4 mRNA is broadly expressed in the peripheral
tissues, whereas protein expression is restricted to activated
B cells, T cells, and monocytes [115]. To date, the cognate
receptor of B7-H4 on activated T cells remained unclear,
although BTLA has been reported as a possible receptor.
Unlike B7-H3, which shows opposite functions, B7-H4
mediates a negative costimulatory signal [116]. B7-H4
strongly inhibited T-cell proliferation and IL-2 secretion,
and its blockade with antagonistic mAbs resulted in in vitroJournal of Biomedicine and Biotechnology 7
enhanced T-cell response and in vivo exacerbation of EAE
[115, 116].
SeveralstudiesreportedtheexpressionofB7-H4inmany
human cancers, such as nonsmall cell lung cancer, ovarian
cancer, prostate cancer, breast cancer, and renal cancer [75].
Recent studies indicate that B7-H4 could be a potential
diagnostic/prognostic marker and/or therapeutic target for
several cancers. In fact, B7-H4 expression was found to
correlate with stage, pathological types, and biological
behavior of many tumors, as shown by retrospective analyses
on 13 types of human cancers. Moreover, the expression
of B7-H4 reverse correlated with the survival of patients
in most cancer analyzed [117]. A recent study by Quandt
et al. demonstrated that the overexpression of B7-H4 in
melanoma cells impaired the antitumor immune response
by decreasing IFN-γ,T N F - α, and IL-2 production [118].
In ovarian cancer, the inhibitory role of B7-H4 might be
due to B7-H4 expression on tumor-associated macrophages
(TAMs). Kryczek et al. showed that B7-H4-expressing TAMs
could block activation of T cells in the setting of ovarian
cancer. B7-H4 expression in TAMs was upregulated by IL-6
and IL-10 present in the tumor microenvironment, whereas
its expression was inhibited by GM-CSF and IL-4. It has
been shown that Treg cells induced APCs to produces IL-
10 and IL-6, providing a new mechanism by which Tregs
exert their suppressive action. B7-H4 blockade by antisense
oligonucleotides restored T-cell antitumor immune response
and led to tumor regression in vivo [119].
Recently, Qian et al. reported the development of a
monoclonalantibodytoB7-H4andpreliminarydatashowed
that it could eﬀectively inhibit the activity of B7-H4,
promoting the growth of T cells and the secretion of IL-2, IL-
4, IL-10, and IFN-γ [120]. Based on these preliminary data,
the blockade of B7-H4 could be an attractive opportunity to
enhance antitumor immunity in a subset of human cancers.
3. The TNF:TNFR Family
3.1. CD40L:CD40. CD40 receptor and its ligand CD40L
(CD154)weretheﬁrstmembersbelongingtotheTNF:TNFR
family to be identiﬁed [121]. CD40 expression has been
originally found on B cells [122], but it is also expressed
on DCs, monocytes, platelets, macrophages as well as
myoﬁbroblasts, ﬁbroblasts, epithelial, and endothelial cells
[121]. CD40L is expressed on activated T and B cells, by
platelets, monocytes, NK cells, mast cells and basophils,
where CD40L is induced following proinﬂammatory stimuli
[121].TheengagementofCD40byCD40LonAPCshasbeen
shown to promote cytokines production and upregulation of
costimulatory molecules, crucial events for T-cell activation,
and diﬀerentiation [123]. CD40L:CD40 signaling in B cells
is also important for the generation of long-lived plasma
cells and memory B cells, as well as for their survival. CD40
intracellular signaling is mediated by the recruitment of
TNFR-associated factors (TRAFs), which in turn activate
diﬀerent pathways, such as the canonical and noncanonical
NF-κB pathway, MAPKs, PI3K and the phospholipase Cγ
pathway [121].
CD40/CD40L pathway is crucial for the development of
antitumor immunity. CD40L blockade resulted in lacking
of protective immune response following administration
of a GM-CSF-expressing B16 melanoma cells vaccine. In
addition, low expression of CD40L was suﬃcient to induce a
long-lasting antitumor immune response via CTLs in a small
number of cancers [4, 121]. The combination of CD40L
expression with other immunomodulators (IL-2, GM-CSF,
and INF-γ) has been found to promote antitumor immunity
in several cancer models. Gene therapy approach with the
use of recombinant adenovirus encoding CD40L was also
eﬀective in colorectal, lung, and melanoma cancer models.
An early study reported that the use of CD40 agonistic
antibodiestriggeredCTL-4responsesinalymphomasystem,
with the consequent tumor eradication [4, 124]. Recently,
the use of activators of both adaptive and innate immunity,
such as CD40 agonists and Toll-like receptor (TLR) ago-
nists, induced antitumor-speciﬁc immunity in many tumor
models [125]. Currently, the combination of CD40 tumor
therapy with other approaches, such as cancer vaccines,
chemotherapy, radiation, CTLA blockade, TLR agonists, and
cytokines, is becoming overriding [125–127].
Another aspect to take into consideration is the direct
eﬀect of CD40:CD40L pathway on tumor cells. Elgueta
et al. reviewed that CD40 is broadly expressed in several
tumors, such as melanoma, prostate cancer, lung cancer,
as well as carcinoma of nasopharynx, bladder, cervix and
ovary, Hodgkin’s and non-Hodgkin’s lymphoma, multiple
myeloma, and acute myeloid leukemia. The engagement of
CD40 on tumor cells can provide growth arrest and apopto-
sis of malignant cells, dependently on type of malignancies
and the microenvironment [121].
To date, three humanized CD40 agonistic antibodies
have been developed: CP-870,893, SGN-40, and HCD 122
(Table 2). CP-870,893 is a fully human, IgG2 antibody that
selectively binds to CD40. It enhances the expression of
MHC class II, CD54, CD86 and CD23 on human B cells
in vitro. CP-870,893 also enhances dendritic cell activity as
demonstrated by secretion of IL-12, IL-23, and IL-8, by the
upregulation of CD86 and CD83, and by the capacity to
prime T cells to secrete IFN-γ [128, 129]. Results from a
phase I study showed that administration of CP-870,893 was
associated with early signs of clinical eﬃcacy, especially in
patients with melanoma [130] .T h es a m ea u t h o r sr e p o r t e d
that weekly infusions of this agonist CD40 antibody were
associated with little clinical activity in advanced cancer
patients [131]. SGN-40 (Dacetuzumab) is a humanized anti-
CD40 monoclonal antibody with multiple mechanisms of
action. In non-Hodgkin lymphoma, Dacetuzumab activates
two distinct proapoptotic signaling pathways; on the one
hand,itconstitutivelyactivatestheNF-κBandMAPKsignal-
ing pathways producing the sustained downregulation of the
oncoprotein B-cell lymphoma 6, which loss results in c-Myc
downregulation and activation of early B-cell maturation,
concomitant with reduced proliferation and cell death. On
the other hand, dacetuzumab induces the expression of
the proapoptotic p53 family member TAp63α and down-
stream proteins associated with the intrinsic and extrinsic
apoptotic machinery [132]. In vitro, dacetuzumab exhibited8 Journal of Biomedicine and Biotechnology
Table 2: Clinical trials of TNF:TNFR costimulatory molecules.
Costimulatory
molecule Tumor model Therapeutic strategy Refs
CD40
Melanoma, Advanced cancers CP-870,893 agonistic Ab anti-CD40 [130, 131]
Myeloma, B-cell lymphoma,
diﬀuse large cell lymphoma SGN-40 agonistic Ab anti-CD40 [134–136]
Multiple myeloma, B-cell
chronic lymphocytic leukemia HCD 122 agonistic Ab anti-CD40 [121]
4-1BB Solid tumors BMS-663513 agonistic Ab anti-4-1BB [148]
OX40 Metastatic prostate cancer Agonistic Ab anti-OX40 [99]
GITR Melanoma TRX518 [99]
CD30 CD30-positive lymphoma Brentuximab vedotin Ab-drug conjugates anti-CD30 [179–182]
antitumor activity against several B-cell lymphoma and mul-
tiple myeloma (MM) cell lines, and induced direct apoptosis
as well as the engagement of eﬀective antibody-dependent
cell-mediated cytotoxicity (ADCC) [133]. Early clinical trials
have evaluated the pharmacokinetics, safety and eﬃcacy
of dacetuzumab in patients with relapsed/refractory B-cell
lymphomas, MM and chronic lymphocytic leukemia [134–
136]. Dacetuzumab resulted in modest antitumor activity in
B-cell lymphomas and, to a lesser extent, in MM. In chronic
lymphocytic leukemia dacetuzumab showed modest activity
as monotherapy, while better results were obtained by using
combinationtherapywithlenalidomide[137].Dacetuzumab
is currently in multiple phase II trials for the treatment
of myeloma and diﬀuse large cell lymphoma. HCD122
is a human IgG1 monoclonal antibody. In B-cell chronic
lymphocytic leukemia, HCD122 exerts antitumor activity by
killing leukemia cells through ADCC and inhibiting CD40L-
inducedsurvivalandproliferationoftumorcells[138].HCD
122isinaphaseItrialforthetreatmentofmultiplemyeloma
and B-cell chronic lymphocytic leukemia [121].
3.2. 4-1BBL:4-1BB. 4-1BB is an inducible costimulatory
receptor expressed on activated CD4+ and CD8+ Tc e l l ,
NKT, NK cells, DCs, macrophages, eosinophils, neutrophils,
and mast cells, as well as Tregs [139, 140]. In the most
cases, 4-1BB is induced on the cellular surface following
activation, except for APCs and Tregs, where its expression
is constitutive [139]. The ligand of 4-1BB is 4-1BBL, which
is expressed on activated professional APCs [139]. 4-1BB:4-
1BBL pathway seems to amplify the existing costimulatory
signals, even if the engagement of 4-1BB in the presence of a
strong TCR signaling can induce IL-2 production in a CD28-
independent manner [141]. Following stimulation with its
ligand, 4-1BB provides costimulatory signals to both CD4+
and CD8+ T cells, with a greater eﬀect on the expansion of
CD8+ duetotheupregulationofantiapoptotic genes,suchas
bcl-XL andbﬂ-1.4-1BBsignalsaremediatedbytheactivation
of NF-κB, c-Jun and p38 downstream pathways [142]. 4-1BB
has also a role in activation of DCs, inducing IL-6 and IL-
12 production and upregulating B7 costimulatory molecules
[142]. 4-1BB plays roles in activating non-T-cells other than
DCs, such as monocytes, B cells, mast cells, NK cells, and
neutrophils and its engagement is associated with cellular
proliferation, cytokine induction, bactericidal activity and
sustenance of T-cell eﬀector functions [139].
Targeting of 4-1BB:4-1BBL pathway in cancer reveals
itself as a promising approach. The adoptive transfer of ex
vivo 4-1BB- and CD28-costimulated T cells induced antitu-
morimmuneresponseinsomepreclinicalstudies[143,144].
Nevertheless,thisapproachseemsnottobeapracticableway,
because of the limits of this application in humans, such as
the small number of ex vivo generated T cells and the risk
of transformation of T cells during in vitro culture [142]. 4-
1BB agonistic antibodies as antitumor therapy were broadly
tested in several animal models with encouraging results.
Melero et al. reported that the intraperitoneal injection
of an antimurine 4-1BB mAb resulted in the eradication
of established P815 mastocytoma and Ag104A sarcoma
in mice [145]. Driessens et al. reviewed of subsequent
studies that demonstrated the eﬃcacy of anti-4-1BB- or 4-
1BBL-expressing tumor cells vaccines in inducing speciﬁc
antitumor T-cell response, suppression of tumor growth
and regression of preestablished tumors in diﬀerent animal
models [4]. Therapeutic eﬀects of agonistic anti-4-1BB mAb
areduetoenhancednaturalkiller(NK)andCD8+ T-cell acti-
vation and IFN-γ production [140]. The current direction
toward which 4-1BB-directed anticancer immunotherapy is
moving is the use of anti-4-1BB mAbs in combination with
other therapeutic approaches, such as antitumor necrosis
factor-related apoptosis inducing ligand (TRAIL), CD40
mAbs, intratumoral delivery of IL-12 gene, DC vaccines,
CTLA-4 blockade, anti-CD4 therapy, chemotherapy, and
radiotherapy [4, 146, 147]. To date, one agonistic anti-4-
1BB-humanized mAb BMS-663513 has been developed and
the functional eﬀects were demonstrated on human and
monkey T cells and peripheral blood mononuclear cells
(PBMCs), where IFN-production was enhanced compared
to controls (Table 2)[ 148]. BMS-663513 is under evaluation
in several phase I and II trials in patients with solid tumors,
showing clinical activity. A phase II randomized study in
melanoma patients with stage IV disease was stopped due to
the occurrence of hepatitis [98, 148, 149].
3.3. OX-40:OX-40L. OX-40 is an inducible costimulatory
receptor expressed on activated CD4+ and CD8+ T cell, but
also on activated Tregs, NKT cells, NK cells, and neutrophilsJournal of Biomedicine and Biotechnology 9
[150]. OX-40L expression is induced on professional APCs,
as well as on T cells, with the aim of amplifying T-cell
responsiveness during T-cell/T-cell interactions [150]. In
addition to APCs, other cell types can induce OX-40L
expression, such as Langerhans cells, mast cells, NK cells,
endothelial cells, and smooth muscle cells [150]. Based
on experimental evidences from OX-40 deﬁcient mice, it
has been reported that this receptor promotes eﬀector T-
cell proliferation and survival, cytokines production, as
well as the generation, and the maintenance of memory T
cells [150]. Moreover, OX-40 inhibits Treg functions and
counteracts the generation of inducible Tregs [150]. OX-40
seems to act as a late positive costimulatory receptor, which
goes on after CD28 signal, in a sequential manner [151]. The
pro-survival activity of OX-40 is in part due to its ability to
upregulate antiapoptotic genes of the Bcl-2 family. In fact,
OX-40 engagement by OX-40L activates both PI3K/Akt and
NF-κBd o w n s t r e a mp a t h w a y s[ 152].
OX-40 represents a promising candidate for cancer
immunotherapy. As reviewed by Croft et al., diﬀerent
approaches have been evaluated, such as agonistic OX-40
mAbs or OX-40L-Ig fusion protein, tumor cells and DCs
transfection with OX40L, and agonist RNA aptamer-binding
OX-40. Treatment with agonistic OX-40 mAbs or OX-40L-
Ig fusion protein resulted in enhanced antitumor immunity
in several cancer models, such as sarcoma, melanoma, colon
carcinoma, and glioma [150]. Several studies also reported
encouraging results following the use of agonistic OX-40
mAbs in combination with IL-12, anti-4-1BB, GM-CSF, DC
vaccine, IL-12, and CD80 costimulation and chemotherapy
[153–156]. Combination therapy with agonistic OX40 mAbs
and cyclophosphamide induces a profound Tregs depletion
in concomitance with an increased inﬁltration of eﬀector
CD8+ T cells in B16 melanoma model [157].
A phase I/II trial is ongoing to evaluate the safety and the
eﬃcacy of a murine anti-human OX40 in combination with
cyclophosphamideandradiationinpatientswithprogressive
metastatic prostate cancer (Table 2). To avoid immune
response to the murine mAb, a humanized OX-40 agonist
has been developed by Agonox, a spinoﬀ biotech company,
and it will be tested in future clinical trials [99].
3.4. Light:HVEM. LIGHT, along with LTα,w a si d e n t i ﬁ e d
as a ligand of the aforementioned HVEM receptor and it
is a member of TNF family [101]. LIGHT expression has
been reported on activated T cells, on immature DCs, on
monocytes and NK cells. LIGTH is not expressed on B cells,
but it can be induced following activation [101]. Experimen-
tal evidences suggested that the interaction HVEM/LIGHT
results in a positive costimulatory signaling, inducing T-cell
proliferation and cytokines production [102]. In fact, the
constitutive expression of LIGHT in T cells of transgenic
miceleadstoaccumulationandactivationofDCsandexpan-
sion of activated eﬀector and memory T cells [158]. More-
over, the manifestation of lymphoproliferative disorders
and autoimmune disease was also observed [159]. LIGHT
deﬁcient mice have been generated and showed defects in
CD8+ T-cell activation and in thymic selection. LIGHT is




of prosurvival and proproliferative genes, as well as genes
regulating cytokines secretion [102]. LIGHT can also engage
the lymphotoxin-β-receptor (LTβR) on DCs and provide
a crucial signaling resulting in DCs expansion, activation
and IL-2 production [102]. Thus, LIGHT can modulate the
immune response both directly by signaling via HVEM on
T cells and indirectly by activating DCs through LTβR. Due
to its role as immunomodulator, LIGHT could be a suitable
target for cancer immunotherapy. The overexpression of
LIGHT in P815 myeloma cell line induces regression of
established tumors in a CD28-independent manner [160];
similar results were obtained upon LIGHT overexpression
in Ag104 sarcoma cell line; in fact, this forced expression
causedrejectionoftumorthroughNK-cellactivation,which,
in turn, triggered tumor-speciﬁc CD8+ T-cell proliferation at
the tumor site [161]. In addition, the injection of LIGHT-
expressing adenoviral vector into primary 4T1 mammary
carcinoma has been found to promote T-cell recruitment,
immunesurveillanceofthetumor,andeliminationofmetas-
tasis [162]. A recent study showed that the LIGHT/HVEM
costimulation through both LIGTH-transfected cells and
HVEM agonistic mAb-induced apoptosis in fresh B-chronic
lymphocytic leukemia cells along with an increased produc-
tion of IL-8 [163]. Another therapeutic approach targeting
LIGHT/HVEM signaling was reported by Park et al., which
developed P815 tumor cell expressing a single-chain variable
fragment (scFv) of an anti-HVEM agonistic monoclonal
antibody on their surface. These authors showed that tumor
cells expressing anti-HVEM scFv spontaneously regress in a
CD4+ and CD8+ T cell-dependent manner when inoculated
in mice and stimulated tumor-speciﬁc long-term T-cell
memory. Moreover, the combination of anti-HVEM scFv-
expressing tumor vaccines and 4-1BB costimulation caused
the regression of established tumors in vivo [164]. Further
studies are needed to clarify the true potential of targeting
this pathway in cancer immunotherapy.
3.5. CD70:CD27. CD27 is another costimulatory receptor
belonging to the TNF family, and it is expressed on na¨ ıve T
and B cells and on NK cells [151]. CD70 has been identiﬁed
asCD27ligandandits expressionis restrictedtoAPCs [151].
The engagement of CD27 by CD70 promotes a positive
costimulatory signaling, resulting in T-cell proliferation and
survival, maybe in concert with CD28 [151]. Recently, a
critical role for CD70 in priming CD8+ T cells has been
demonstrated [165]. The stimulatory role of this pathway
is conﬁrmed by the observation that CD70 and CD27
transgenic mice developed autoimmune diseases [166]. Like
other members of the TNFR family, CD27 signaling is medi-
ated by the recruitment of TRAF proteins [167]. Targeting
CD27 could represent an attractive strategy in the ﬁeld of
cancer immunotherapy. Driessens et al. reviewed about early
studies reporting that the overexpression of CD70 promoted
cancer elimination through the activation of T cells and NK
cells [4]. In addition, the potential of costimulatory ligand
CD70 to boost DC-based vaccine capacity to evoke eﬀective10 Journal of Biomedicine and Biotechnology
CD8+ T-cell immunity has been explored [168]. Glouchkova
et al. suggested that the modulation of the CD70/CD27
pathway might represent a novel therapeutic approach for
enhancing the antileukemic response in B-cell precursor
acute lymphoblastic leukemia [169]. Recently, agonistic anti-
CD27antibodieshasshowntobeeﬀectiveasmonotherapyin
reducing the outgrowth of experimental lung metastases and
established subcutaneous melanoma tumors in vivo [170].
In addition to CD70 agonists, the soluble form of CD70
has been evaluated as powerful adjuvant in a glioblastoma
model [171]. The aberrant expression of CD70 in a broad
range of hematological malignancies and in some solid
tumors has led to the development of CD70-speciﬁc T
cells, having a CAR receptor consisting of CD27 fused to
the CD3- chain. Recently, adoptively transferred CD70-
speciﬁc T cells have been found to induce regression of
established murine xenografts through the recognition of
CD70-expressing tumor cells [172].
3.6. GITRL:GITR. Glucocorticoid-induced TNFR-related
protein (GITR) is a costimulatory receptor expressed on
activated T cells and, constitutively, on Tregs [173]. Its
ligand GITRL is expressed at low levels on APCs, but it gets
induced following TLR stimulation [173]. Several studies
havereportedthatGITRsignalingpromotestheproliferation
of na¨ ıve T cells and cytokines production through the
recruitment of TRAF proteins and the activation of down-
stream pathways [174]. Moreover, one of the ﬁrst described
GITR function was the ability to protect T cells from
activation-induced cell death. Controversial data have been
reported about the regulation of Treg functions by GITR. In
fact, experimental evidences suggest both an inhibitor and a
stimulatory role for GITR [174]. The modulation of GITR
pathway is an intriguing therapeutic possibility.
The treatment with GITR-expressing adenovirus vector
has been shown to be able to induce T-cell response and
to reduce tumor size in mice inoculated with B16 tumor
cells [175]. Nishikawa et al. reported that triggering GITR
throughGITRL-expressingplasmidresultedintheinhibition
of tumor growth in a CMS5 sarcoma model. The protection
of CD8+ T cell against Treg-mediated suppression was also
observed by the authors [176]. The use of GITR agonistic
antibody (clone DTA-1) is also eﬀective in stimulating
antitumor immunity in vivo [174]. Recently, Zhou et al.
suggested that the antitumor eﬀect of anti-GITR antibody
was dependant on its ability to positive costimulate T cells
rather than to suppress Treg functions, but the question is
still debated [177]. Last year, a clinical study of an agonist
anti-GITR antibody (TRX518) in melanoma was started but
the trial was put on hold in March because of a major
business setback of the company that makes the antibody
(Table 2)[ 99].
3.7. CD30L:CD30. CD30 receptor is an inducible costimu-
latory receptor expressed on activated and memory T cells
following TCR/CD28 or IL-4 stimulation [178]. The ligand
of CD30 is CD30L, which is expressed on activated T cells,
as well as on macrophages, dendritic cells, and B cells [178].
CD30L/CD30 signaling seems to be involved in Th1 and Th2
cell responses and plays a critical role in Th17 diﬀerentiation
[178]. The costimulatory signal provided by CD30L:CD30
is not yet at all clear, but it seems to be involved in the
peripheral costimulation, mainly supporting T-cell survival,
with overlapping features of OX-40 and 4-1BB pathways
[167]. Due to the expression of CD30 on all malignant
Hodgkin and Reed-Sternberg cells (HRS), this receptor
represents an important target for the immunotherapy of
hematological malignancies. SGN-35 (brentuximab vedotin)
is an anti-CD30 antibody that has been modiﬁed by the
additionofadipeptidelinkertopermitattachmentofmicro-
tubule polymerization monomethylauristatin E (MMAE)
(Table 2)[ 179] .S G N - 3 5h a sb e e ne v a l u a t e di np h a s eId o s e -
escalation study in 45 patients with relapsed or refractory
CD30-positive hematologic malignancies and the maximum
tolerated dose was determined to be 1.8mg/kg [180]. In
a pivotal phase II study of SGN-35, 102 patients with
relapsed or refractory Hodgkin lymphoma were treated with
1.8mg/kg dose of SGN-35 every three weeks. A reduction
in tumor volume was observed in 95% of patients and the
overall response rate (ORR) was 75% [181]. The eﬃcacy of
SGN-35 has been also evaluated in a phase II single-arm
studyin58patientswithanaplasticlargecelllymphoma.The
authorsreported thattheORRwas86% [182].Amulticenter
randomized phase III trial of SGN-35 (AETHERA) in
posttransplant classical Hodgkin lymphoma patients at high
risk for recurrence was started in April 2010 and it should
be completed in June 2013. In the light of these impressive
result, the FDA approved SGN-35 for the treatment of
Hodgkin lymphoma in August 2011. The high eﬃcacy of
this antibody-drug conjugate could be due to the fact that
cytotoxic eﬀect of MMAE targets not only CD30-expressing
HRS cells, but also the immune suppressive Tregs present in
the tumor microenvironment because of a bystander eﬀect;
moreover, SGN-35 delivers itself an additional apoptotic
signal, mainly in anaplastic large cell lymphoma cells [179].
4. Conclusions
Improving the knowledge of T costimulatory and coin-
hibitory pathways reached over the past decade shed light on
the central roles that these molecules play in the generation
of an eﬀective immune response. Many tumors escape
from immune surveillance through the downregulation of
positive costimulatory molecules and the upregulation of
coinhibitory signals. Blockade of coinhibitory pathway on
the one hand and the stimulation of the positive signals on
the other hand have been found to enhance antitumoral
immunity, both alone and in combination with traditional
therapy in preclinical and clinical trials. Further studies are
necessary to evaluate the safety and the eﬃcacy of these
approaches before using them in the clinical practice.
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